Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04686851
Other study ID # PROGNOSIS-RCT
Secondary ID R247-A1438220/ 1
Status Recruiting
Phase N/A
First received
Last updated
Start date November 1, 2020
Est. completion date June 1, 2024

Study information

Verified date December 2023
Source Odense University Hospital
Contact Jesper Ryg, MD
Phone 60152610
Email Jesper.Ryg@rsyd.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Randomized Clinical Trial examining the effects of Comprehensive Geriatric Assessment as an add on to oncologic treatment. Participants included are cancer patients found eligible for oncologic treatment, age 70 or more, and screened frail with the Geriatric 8 screening tool.


Description:

This study aims to examine the effects of Comprehensive Geriatric Assessment and interventions on prognosis in the older frail cancer patient in a Randomized Clinical Trial design. Patients screened frail with the Geriatric 8 screening tool, aged 70 or more, and found eligible for oncologic treatment, will be included. We plan to enrol a total of 322 cancer patients for 12 months. Participants will be allocated randomly to either interventional or control group. Participants in the interventional group will be offered a Comprehensive Geriatric Assessment and intervention at the start-up of cancer treatment. The Comprehensive Geriatric Assessment will be an add on to standardized cancer treatment offered at the Oncologic Outpatient Clinic at Odense University Hospital. Comprehensive Geriatric Assessment will be performed by a team consisting of a doctor, nurse and physiotherapist. If needed, referral to a dietician or an occupational therapist for further evaluation will be made. The health issues are assessed using validated tests based on a Danish version of the Geriatric Core Dataset (G-CODE). Follow-up on Comprehensive Geriatric Assessment is scheduled for one month after initial evaluation. The randomized groups will be compared with respect to primary and secondary endpoints.


Recruitment information / eligibility

Status Recruiting
Enrollment 322
Est. completion date June 1, 2024
Est. primary completion date November 1, 2023
Accepts healthy volunteers No
Gender All
Age group 70 Years and older
Eligibility Inclusion Criteria: - Age = 70 years - Living in the region of Southern Denmark - Newly diagnosed solid tumours assessed eligible for antineoplastic treatment - Vulnerable or frail (G8 = 14) Exclusion Criteria: - Inability to speak or understand Danish - Inability to give informed consent - Already consulting geriatric outpatient clinic - Already receiving active treatment for other coexisting solid tumours, haematologic cancers, or non-melanoma skin cancer or has received oncologic treatment the past year

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Comprehensive Geriatric Assessment and follow-up
All patients will receive standardized oncological treatment according to national guidelines. For patients randomized to the intervention arm, a full Comprehensive Geriatric Assessment (CGA) and corresponding interventions on identified health issues will be performed alongside oncologic treatment. The domains are assessed using validated tests based on a Danish version of the Geriatric Core Dataset (G-CODE). The domains are cognition, mood, comorbidity, functional status, physical status, polypharmacy, nutrition, fall risc and social support. The CGA will be performed by the PhD-student (geriatric resident) or a geriatrician together with geriatric nurses at the Department of Geriatric Medicine, OUH. Nutritional status and interventions are assessed by a dietician. A physical therapist will evaluate the physical performance as part of the CGA. Follow-up on initial treatment plan is scheduled to one month after baseline CGA.

Locations

Country Name City State
Denmark Odense University Hospital Odense Southern Denmark

Sponsors (6)

Lead Sponsor Collaborator
Odense University Hospital Academy of Geriatric Cancer, Danish Cancer Society, Odense Patient Data Explorative Network, Region of Southern Denmark, University of Southern Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary physical function for patients receiving palliative oncologic treatment measured by 30 seconds Chair Stand Test, number of repetitions in a 30 seconds time period. 3 months
Primary unplanned hospital admissions for patients receiving adjuvant oncologic treatment number of unplanned hospitalisations including admissions to Oncologic Department, Emergency Department and Medical Departments. Data will be retrieved trough review of electronic medical records. 6 months
Secondary Physical functional for patients receiving curative oncologic treatment measured by 30 seconds Chair Stand Test, number of repetitions in a 30 seconds time period. 3 months
Secondary Physical functional for patients receiving curative oncologic treatment measured by 30 seconds Chair Stand Test, number of repetitions in a 30 seconds time period. 6 months
Secondary Physical functional for patients receiving palliative oncologic treatment measured by 30 seconds Chair Stand Test, number of repetitions in a 30 seconds time period. 6 months
Secondary number of unplanned hospital admissions for patients receiving palliative oncologic treatment Number of unplanned hospitalisations including admissions to Oncologic Department, Emergency Department and Medical Departments. Data will be retrieved trough review of electronic medical records. 6 months
Secondary Health-related Quality of life Measured by EORTC-QLQ-C30 12 months
Secondary Health-related Quality of life Measured by EORTC-QLQ-ELD14 12 months follow-up
Secondary Elderly Functional Index Score (ELFI-score) Self reported functioning score. It is a composite score derived from the three scales "physical functioning", "Role functioning" and Social Functioning", from the quality of life questionnaire EORTC-QLQ-C30 and the scale "Mobility" from the quality of life questionnaire EORTC-QLQ-ELD-14. The range is (12-48), with a higher score being a better outcome. 6 months
Secondary Number of patients who experience oncologic treatment toxicity Treatment toxicity grade 3+ evaluated with Common Terminology Criteria for Adverse Events 6 months
Secondary Number of patients with adherence to initial oncologic treatment plan Registration of dose reductions, discontinuations and delays of intended cancer treatment. 6 months
Secondary Degree of Polypharmacy (PP) Degree of polypharmacy. Polypharmacy is defined as daily use of more than 5 prescription drugs. 3 months
Secondary Number of potential Inappropriate Medications (PIM) Using the Screening Tool for Older Persons Prescriptions (STOPP) criteria. Number of PIM will be registered for each patient 3 months
Secondary Number of Potential Drug Interactions (PDI) Using Stockley's Drug Interaction Database. Number of PDI will be registered for each patient 3 months
Secondary Overall survival Measured from Geriatric 8 screening to time of death 12 months
Secondary Cancer specific survival Measured from Geriatric 8 screening to time of death in patients with residual cancer 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients